Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways

Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways

The renin-angiotensin-aldosterone system (RAAS) is a hormone system that controls blood pressure and fluid and electrolyte balance. Angiotensin II, a key effector, is produced from angiotensin I by angiotensin-converting enzyme (ACE) and exerts its effects through binding to its type 1 (AT1R) or typ...

Full description

Saved in:

Bibliographic Details
Main Author:	Ulvi Bayraktutan
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Current Issues in Molecular Biology
Subjects:	angiotensin II renin-angiotensin system cardiovascular disease oxidative stress smooth muscle cell proliferation angiotensin converting enzyme
Online Access:	https://www.mdpi.com/1467-3045/47/7/501
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis
by: Changhui Lang, et al.
Published: (2025-07-01)

RENIN-ANGIOTENSIN SYSTEM IN REGULATION OF HEMATOPOIESIS
by: M. L. Kanaeva, et al.
Published: (2018-02-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
by: Juan Meng, et al.
Published: (2020-01-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Angiotensin II and COVID-19. Secrets of interactions
by: A. O. Konradi, et al.
Published: (2020-05-01)

ANGIOTENSIN II RECEPTOR TYPE 1 EXPRESSION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS
by: I. S. Mykhailichenko
Published: (2016-04-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Variation of Concentrations of Angiotensin II, AngiotensinConverting Enzyme and Matrix Metalloprotease-9 in Tears and Serum of Patients with Diabetic Retinopathy
by: V. V. Neroev, et al.
Published: (2020-12-01)

Angiotensin Converting Enzyme Inhibitors: Interaction Issues in Patients with Glaucoma and Arterial Hypertension. Review
by: S. I. Makogon, et al.
Published: (2023-12-01)

The systemic angiotensin-II role in the development of retinopathy of prematurity
by: N. A. Osipova, et al.
Published: (2023-07-01)

Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
by: Bilgehan Karadağ
Published: (2020-07-01)

Alterations in the renin-angiotensin system during septic shock
by: Camille Benaroua, et al.
Published: (2025-03-01)

Modulation of the renin-angiotensin system against COVID-19: A path forward?
by: Serge Camelo, et al.
Published: (2025-05-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study
by: Weihong Zeng, et al.
Published: (2025-05-01)

MECHANISMS OF COMBINED ACTION OF ACE INHIBITORS AND CALCIUM ANTAGONISTS IN ARTERIAL HYPERTENSION
by: E. I. Astashkin, et al.
Published: (2013-06-01)

Preoperative continuation vs. discontinuation of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on early cognitive function in elderly patients undergoing noncardiac surgery: a randomized controlled trial
by: Xiaohan Wang, et al.
Published: (2025-03-01)

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients
by: Ali Kaan Güren, et al.
Published: (2025-04-01)

Prospects of using genetic testing to increase the effectiveness of antihypertensive therapy
by: N. V. Drobotya, et al.
Published: (2020-06-01)

Pulse Pressure Index as a Discriminator of Predicting the Cardiovascular Events in Hypertensive Patients Treated with Drugs Acting on Angiotensinogen-Angiotensin Pathway
by: Marwan S. Al-Nime, et al.
Published: (2019-06-01)

The use of angiotensin-converting enzyme inhibitors in general medicine
by: M.L.I. Mashitisho
Published: (2012-08-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

Duration of rheumatoid arthritis changes blood levels of angiotensin and aldosterone
by: Boris A. Rebrov, et al.
Published: (2023-12-01)

The Renin–Angiotensin System Modulates SARS-CoV-2 Entry via ACE2 Receptor
by: Sophia Gagliardi, et al.
Published: (2025-07-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Association of insertion deletion polymorphism of the ACE gene with factors of circulating rennin-angiotensin-aldosterone system and endothelial function of skin microvassals in preeclampsia
by: O. V. Radkov, et al.
Published: (2011-08-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES
by: K. A. Gyamdzhyan, et al.
Published: (2015-12-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

Myocardial and Renal Renin–Angiotensin System Enzyme Activity in Dogs
by: Emma C. Weitzhandler, et al.
Published: (2025-07-01)

EFFECTS OF VITAMIN D ON THE RENIN-ANGIOTENSIN SYSTEM
by: L. Pashova-Stoyanova, et al.
Published: (2019-09-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)